Abstract
In a controlled trial, baclofen (mean dose 45 mg daily) signficantly increased disability from Parkinsonism in 12 patients with the long-term levodopa syndrome. Peak dose choreoathetosis was not improved but benefit was observed in all four patients with "off period dystonia." Adverse side effects were common and severe, and included visual hallucinations, vomiting, and dizziness.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Andén N. E., Wachtel H. Biochemical effects of baclofen (beta-parachlorophenyl-GABA) on the dopamine and the noradrenaline in the rat brain. Acta Pharmacol Toxicol (Copenh) 1977 Feb;40(2):310–320. doi: 10.1111/j.1600-0773.1977.tb02083.x. [DOI] [PubMed] [Google Scholar]
- Barbeau A. Letter: G.A.B.A. and Huntington's chorea. Lancet. 1973 Dec 29;2(7844):1499–1500. doi: 10.1016/s0140-6736(73)92765-7. [DOI] [PubMed] [Google Scholar]
- Bigelow L. B., Nasrallah H., Carman J., Gillin J. C., Wyatt R. J. Baclofen treatment in chronic schizophrenia: a clinical trial. Am J Psychiatry. 1977 Mar;134(3):318–320. doi: 10.1176/ajp.134.3.318. [DOI] [PubMed] [Google Scholar]
- Davies J., Watkins J. C. The action of beta-phenyl-GABA derivatives on neurones of the cat cerebral cortex. Brain Res. 1974 Apr 26;70(3):501–505. doi: 10.1016/0006-8993(74)90258-3. [DOI] [PubMed] [Google Scholar]
- Frederiksen P. K. Letter: Baclofen in the treatment of schizophrenia. Lancet. 1975 Mar 22;1(7908):702–702. doi: 10.1016/s0140-6736(75)91819-x. [DOI] [PubMed] [Google Scholar]
- Fuxe K., Hökfelt T., Ljungdahl A., Agnati L., Johansson O., Perez de la Mora M. Evidence for an inhibitory gabergic control of the meso-limbic dopamine neurons: possibility of improving treatment of schizophrenia by combined treatment with neuroleptics and gabergic drugs. Med Biol. 1975 Jun;53(3):177–183. [PubMed] [Google Scholar]
- Gerlach J. The relationship between parkinsonism and tardive dyskinesia. Am J Psychiatry. 1977 Jul;134(7):781–784. doi: 10.1176/ajp.134.7.781. [DOI] [PubMed] [Google Scholar]
- Korsgaard S. Baclofen (Lioresal) in the treatment ofneuroleptic-induced tardive dyskinesia. Acta Psychiatr Scand. 1976 Jul;54(1):17–24. doi: 10.1111/j.1600-0447.1976.tb00090.x. [DOI] [PubMed] [Google Scholar]
- Lees A. J., Shaw K. M., Stern G. M. "Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease. Lancet. 1977 Nov 12;2(8046):1034–1034. doi: 10.1016/s0140-6736(77)92939-7. [DOI] [PubMed] [Google Scholar]
- Olpe H. R., Koella W. P., Wolf P., Haas H. L. The action of baclofen on neurons of the substantia nigra and of the ventral tegmental area. Brain Res. 1977 Oct 14;134(3):577–580. doi: 10.1016/0006-8993(77)90834-4. [DOI] [PubMed] [Google Scholar]
- Walinder J., Wallin L., Carlsson A. Effect of baclofen on cerebrospinal-fluid levels of 5-hydroxyindoleacetic acid and homovanillic acid. N Engl J Med. 1977 Feb 24;296(8):452–453. doi: 10.1056/nejm197702242960816. [DOI] [PubMed] [Google Scholar]